Bayer Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bill Anderson
Chief executive officer
€8.8m
Total compensation
| CEO salary percentage | 25.4% |
| CEO tenure | 2yrs |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Bayer (ETR:BAYN) Has A Somewhat Strained Balance Sheet
Dec 28
Innovative Launches And Decisive Moves Set Stage For Remarkable Growth In Pharmaceuticals And Consumer Health
Nov 24 Pharmaceutical and agriculture innovations are key strategies for growth, offsetting generic competition and boosting future revenues.Benign Growth For Bayer Aktiengesellschaft (ETR:BAYN) Underpins Stock's 25% Plummet
Nov 21These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Sep 13Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now
Aug 09These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Jun 11The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet
May 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €9m | €2m | -€3b |
| Sep 30 2024 | n/a | n/a | -€880m |
| Jun 30 2024 | n/a | n/a | -€1b |
| Mar 31 2024 | n/a | n/a | -€3b |
| Dec 31 2023 | €12m | €2m | -€3b |
Compensation vs Market: Bill's total compensation ($USD10.04M) is above average for companies of similar size in the German market ($USD5.29M).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
CEO
Bill Anderson (58 yo)
2yrs
Tenure
€8,842,000
Compensation
Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Management Board & CEO | 2yrs | €8.84m | no data | |
| CFO & Member of Management Board | 7yrs | €3.63m | no data | |
| Head of the Pharmaceuticals Division & Member of the Board of Management | 6.4yrs | €3.68m | no data | |
| Member of Management Board & President of the Crop Science Division | 3.3yrs | €3.77m | no data | |
| Chief Talent Officer | 1.6yrs | €3.79m | no data | |
| Member of Management Board & President of Consumer Health Division | 1yr | €3.58m | no data | |
| Chief Operating Officer | 1yr | no data | no data | |
| Chief Information Officer | 1.3yrs | no data | no data | |
| Head of Investor Relations | 1.5yrs | no data | no data | |
| Head of Law | 1.8yrs | no data | no data | |
| Head of Communications | 8.9yrs | no data | no data | |
| Head of Group Finance | no data | no data | no data |
1.8yrs
Average Tenure
56yo
Average Age
Experienced Management: BAYN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | 23yrs | €231.00k | no data | |
| Independent Member of the Supervisory Board | 5.5yrs | €248.00k | no data | |
| Independent Member of Supervisory Board | 8yrs | €227.00k | no data | |
| Chairman of Executive Board - Bayer Business Services | no data | no data | no data | |
| Independent Supervisory Board Member | 1yr | €188.00k | no data | |
| Independent Member of Supervisory Board | 5yrs | €331.00k | no data | |
| Vice Chairwoman of Supervisory Board | 8yrs | €347.00k | no data | |
| Member of Supervisory Board | 13yrs | €271.00k | no data | |
| Member of Supervisory Board | 9.4yrs | €268.00k | no data | |
| Independent Chairman of Supervisory Board | 6.9yrs | €510.00k | no data | |
| Member of Supervisory Board | 4.6yrs | €240.00k | no data | |
| Chairman of Executive Board - Currenta | no data | no data | no data |
7.5yrs
Average Tenure
66.5yo
Average Age
Experienced Board: BAYN's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 05:25 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bayer Aktiengesellschaft is covered by 54 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| null null | Banco de Sabadell. S.A. |
| Emily Field | Barclays |